<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">555</journal-id><journal-id journal-id-type="pmc-domain">currneuro</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title-group><journal-title>Current Neuropharmacology</journal-title></journal-title-group><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10556391</article-id><article-id pub-id-type="pmcid-ver">PMC10556391.1</article-id><article-id pub-id-type="pmcaid">10556391</article-id><article-id pub-id-type="pmcaiid">10556391</article-id><article-id pub-id-type="pmid">37013426</article-id><article-id pub-id-type="doi">10.2174/1570159X21666230403080624</article-id><article-id pub-id-type="publisher-id">CN-21-2195</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Medicine, Neurology, Pharmacology, Neuroscience</subject></subj-group></article-categories><title-group><article-title>Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Di Nicola</surname><given-names initials="M">Marco</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pepe</surname><given-names initials="M">Maria</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panaccione</surname><given-names initials="I">Isabella</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moccia</surname><given-names initials="L">Lorenzo</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Janiri</surname><given-names initials="L">Luigi</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sani</surname><given-names initials="G">Gabriele</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Psychiatry</institution>, <institution>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</institution>, <addr-line><city>Rome</city></addr-line>, <country country="it">Italy</country>;</aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Neuroscience, Section of Psychiatry</institution>, <institution>Universit&#224; Cattolica del Sacro Cuore</institution>, <addr-line><city>Rome</city></addr-line>, <country country="it">Italy</country>;</aff><aff id="aff3"><label>3</label><institution>Mental Health Department</institution>, <addr-line>ASL Roma 1</addr-line>, <addr-line><city>Rome</city></addr-line>, <country country="it">Italy</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Neuroscience, Section of Psychiatry, Universit&#224; Cattolica del Sacro Cuore, Rome, Italy; Tel/Fax: +39 06/30154122-7097; E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marco.dinicola@policlinicogemelli.it">marco.dinicola@policlinicogemelli.it</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2023</year></pub-date><volume>21</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">446835</issue-id><fpage>2195</fpage><lpage>2205</lpage><history><date date-type="received"><day>28</day><month>10</month><year>2022</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-10 18:25:10.117"><day>10</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Bentham Science Publishers</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Bentham Science Publishers</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>&#169; 2023 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/legalcode</uri>)</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CN-21-2195.pdf"/><abstract><sec><title>Background</title><p> Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are major public health concerns because of their high prevalence and clinical and functional severity. MDD and AUD commonly co-occur, but effective therapeutic approaches for comorbidity are still scarce. Available evidence on selective serotonin reuptake inhibitors and tricyclic antidepressants held mixed results, and further pharmacological categories have been less investigated. Trazodone is an approved antidepressant drug for adults and has shown efficacy on symptoms like anxiety and insomnia observed in AUD patients as well. Thus, this study aims to evaluate the effect of extended-release trazodone on clinical and functional features in MDD + AUD subjects.</p></sec><sec><title>Methods</title><p> One hundred MDD + AUD outpatients were retrospectively evaluated at 1, 3, and 6 months of treatment with extended-release trazodone (150-300 mg/day, flexibly dosed). Improvement in depressive symptoms was the primary outcome measure. Changes in anxiety, sleep, functioning, quality of life, clinical global severity, and alcohol craving were also investigated.</p></sec><sec><title>Results</title><p> Trazodone reduced depressive symptoms (<italic toggle="yes">p &lt;</italic> 0.001) with 54.5% remission at the endpoint. Similar improvements were observed in all secondary outcomes, including anxiety, sleep alterations, and craving (<italic toggle="yes">p &lt;</italic> 0.001). Only mild side effects were reported and disappeared over time.</p></sec><sec><title>Conclusion</title><p> Extended-release trazodone displayed good antidepressant properties in MDD + AUD patients, ameliorating overall symptomatology, functioning, and quality of life, with a good safety/ tolerability profile. Further, it significantly improved sleep disturbances and craving symptoms, which are associated with drinking relapse and worse outcomes. Therefore, trazodone might represent a promising pharmacological option for MDD + AUD patients.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Trazodone</kwd><kwd>comorbidity</kwd><kwd>depression</kwd><kwd>alcoholism</kwd><kwd>antidepressants</kwd><kwd>personalized medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>INTRODUCTION</title><p>Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are highly prevalent diseases and are associated with increased rates of morbidity, disability, and mortality. MDD affects about 300 million people worldwide and is expected to become the leading cause of disability by 2030 [<xref rid="r1" ref-type="bibr">1</xref>]. Similarly, more than 100 million people can be diagnosed with AUD, although only a minority seeks help [<xref rid="r2" ref-type="bibr">2</xref>].</p><p>MDD and AUD are frequently comorbid, with MDD being the psychiatric disorder most found in subjects with AUD, and the presence of either condition doubles the risk of developing the other [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r4" ref-type="bibr">4</xref>]. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) differentiates primary depression from substance-induced disorders; thus, a diagnosis of depression during active drinking or alcohol withdrawal should be made with caution. Accordingly, current guidelines indicate that in MDD + AUD patients, antidepressant treatment should be started only after about 4-weeks of abstinence from alcohol, a period that allows diagnosing an independent depressive disorder with more confidence. Nonetheless, it has been reported that more than &#188; of AUD patients experienced a substance-induced depressive episode in their lifetime [<xref rid="r5" ref-type="bibr">5</xref>]. It is also evident that substance-induced depression itself increases the risk for independent depressive disorders. Also, a significant rate of cases initially diagnosed as &#8220;substance-induced&#8221; are later reclassified as &#8220;primary&#8221; depression, thus encouraging to consider antidepressant treatment in these patients [<xref rid="r6" ref-type="bibr">6</xref>].</p><p>Repeated evidence highlights the association of comorbid MDD + AUD with increased symptom severity, worse response to treatments, and detrimental clinical and functional outcomes [<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r7" ref-type="bibr">7</xref>]. A recent study has shown that subjects with depression/anxiety have a particularly high risk of alcohol misuse immediately before starting the antidepressant therapy [<xref rid="r8" ref-type="bibr">8</xref>], which might reflect the worsening of substance use problems alongside the worsening of mood/anxiety symptoms. In addition, alcohol use negatively affects the frequency and duration of depressive episodes and is associated with a higher suicide risk [<xref rid="r9" ref-type="bibr">9</xref>]. Moreover, among patients with AUD, depressive symptoms can increase the risk of both mood-induced episodes of heavy drinking and relapse during early abstinence, while individuals who never had depressive or anxiety disorders seem to be more likely to achieve remission [<xref rid="r10" ref-type="bibr">10</xref>]. Additionally, specific features, <italic toggle="yes">i.e</italic>., anxiety and insomnia, seem to be particularly associated with a higher risk of both mood and drinking relapses, and could benefit from targeted interventions [<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref>]. However, despite the significance of MDD + AUD comorbidity, these patients tend to be excluded from registration trials, and existing guidelines mostly focus on either disorder.</p><sec id="sec1.1"><label>1.1</label><title>Management of MDD + AUD: Evidence from the Literature</title><p>Several meta-analyses and systematic reviews summarized the available evidence on the efficacy of both psychopharmacological and psychosocial interventions more commonly employed in clinical practice for addressing MDD + AUD.</p><p>A meta-analysis of placebo-controlled randomized clinical trials (RCTs) showed that certain antidepressants (<italic toggle="yes">i.e</italic>., tricyclic antidepressants (TCAs), nefazodone) were more effective than placebo in treating depression in comorbid MDD + AUD patients [<xref rid="r13" ref-type="bibr">13</xref>]. A subsequent systematic review assessed the risks and benefits of antidepressants in MDD + AUD patients by investigating clinical trials comparing antidepressants, alone or in association with other drugs or psychosocial interventions (or both) <italic toggle="yes">vs.</italic> placebo, no treatment, and other pharmacological or psychosocial interventions [<xref rid="r14" ref-type="bibr">14</xref>]. Results from this study reported some efficacy of several classes of antidepressants in improving both depressive symptoms and certain AUD-related features, such as the number of drinks per drinking day and the percentage of patients maintaining abstinence [<xref rid="r14" ref-type="bibr">14</xref>]. Although results were not always consistent across the studies, subsequent reviews supported the use of psychopharmacotherapy for comorbid MDD + AUD and highlighted the importance of concurrently treating both conditions to achieve better clinical outcomes [<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r16" ref-type="bibr">16</xref>]. A bayesian network meta-analysis of RCTs on pharmacological treatments of MDD + AUD [<xref rid="r9" ref-type="bibr">9</xref>] aimed at comparing and ranking the efficacy of current treatments on both mood- and AUD-related outcomes. Results have shown that monotherapy with either antidepressants or anti-craving drugs was insufficient in addressing concurrent symptoms, supporting the need for a combined therapy despite the increased tolerability concerns. A network meta-analysis further confirmed the abovementioned findings, suggesting that treatment with TCAs and Selective Serotonin Reuptake Inhibitors (SSRIs) improves depressive symptoms and functional status in patients dually diagnosed, while effects on drinking outcomes appeared to be less relevant [<xref rid="r17" ref-type="bibr">17</xref>]. By contrast, a recent bayesian meta-analysis on 64 RCTs with 6128 participants found that SSRIs (specifically fluoxetine) not only improved depressive symptoms in individuals with AUD but also facilitated abstinence and reduced alcohol use and craving independently of dosage or treatment length [<xref rid="r18" ref-type="bibr">18</xref>].</p><p>Recent clinical studies have shown as well that SSRIs improved both depressive symptoms and craving measures [<xref rid="r19" ref-type="bibr">19</xref>] and confirmed the efficacy of fluoxetine, fluvoxamine, and citalopram in treating depression in MDD + AUD patients, with statistically significant differences related to the presence of CYP polymorphisms [<xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r22" ref-type="bibr">22</xref>]. However, these findings were limited by the small sample size, the heterogeneity of inclusion criteria, and the lack of a control group.</p><p>So far, investigations on MDD + AUD have focused mainly on the effects of SSRIs and different classes of antidepressants have been less investigated.</p><p>Two recent, preliminary, real-world studies highlighted the effectiveness of vortioxetine in improving depressive symptoms in MDD + AUD patients, with also beneficial effects in reducing alcohol consumption [<xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r24" ref-type="bibr">24</xref>]. New antidepressants with glutamatergic activity (<italic toggle="yes">i.e</italic>., ketamine, esketamine), recently approved for treatment-resistant depression, are currently being tested for further conditions [<xref rid="r25" ref-type="bibr">25</xref>]. A case series on comorbid MDD + AUD patients described that treatment with naltrexone and ketamine was associated with improvement in depressive symptoms, as well as in alcohol craving and consumption [<xref rid="r26" ref-type="bibr">26</xref>]. However, these observations will need to be replicated in much larger studies with different designs to provide informative results.</p></sec><sec id="sec1.2"><label>1.2</label><title>Limitations and &#8216;Unmet Needs&#8217; of Systematic Reviews, Meta-analyses, and RCTs</title><p>Despite the substantial efforts to systematically analyze the available evidence and the most recent clinical trials, to date, results are not consistent enough to inform guideline recommendations. Several reasons could be argued.</p><p>First, the relatively small number of clinical studies on comorbid MDD + AUD patients, especially RCTs. Second, the diagnosis of comorbid MDD and AUD might be challenging because of overlapping symptoms and shared features, like the depressant effects of alcohol, insomnia, and psychomotor agitation. Diagnostic criteria for AUD varied between DSM-IV and DSM-5, and depressive disorders include several conditions with different features. Also, clinical studies included in systematic analyses differ in terms of enrolling MDD + AUD patients with active drinking or recently sober. All these factors might have contributed to increased heterogeneity of the sample within studies and limited the consistency of results. Third, most clinical trials compared the effects of antidepressants <italic toggle="yes">vs</italic>. placebo, and only a few studies with small sample sizes included active comparators so it is currently not possible to define whether specific compounds might prove superior efficacy. Finally, there is a substantial disproportion in the number of available studies that employed TCAs and SSRIs, while molecules with different mechanisms of action have been less investigated.</p><p>Despite these limitations, systematic studies agree that antidepressants may be useful therapeutic options in people with co-occurring depressive and alcohol-use disorders.</p></sec><sec id="sec1.3"><label>1.3</label><title>New Potential Perspectives for Treatment</title><p>Given the high prevalence of comorbid MDD + AUD, its detrimental outcomes, the burden on the healthcare system, and the relevance of unmet needs, defining therapeutic approaches that effectively address both conditions is urgent.</p><p>Neuromodulation interventions have been increasingly studied as treatment options for several psychiatric disorders. Repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) are non&#8208;invasive and safe techniques used to inhibit or promote local neural activity in specific cortical areas that have been mainly investigated in mood and obsessive-compulsive disorders [<xref rid="r27" ref-type="bibr">27</xref>, <xref rid="r28" ref-type="bibr">28</xref>]. Repetitive TMS is an evidence-based treatment for MDD [<xref rid="r29" ref-type="bibr">29</xref>] and promising evidence has been raising in the addiction field, especially for the treatment of substance use disorders [<xref rid="r30" ref-type="bibr">30</xref>]. Findings from a real-world study on subjects with substance and alcohol use disorders show a significant and rapid reduction of craving following 5 consecutive days of tDCS sessions, alongside improvement in depressive and anxious symptoms, consistent with previous studies [<xref rid="r30" ref-type="bibr">30</xref>, <xref rid="r31" ref-type="bibr">31</xref>]. Such results, together with the wider experience achieved on depressive disorders, suggest that synergistic approaches combining pharmacological treatments, psychotherapies, and neuromodulation strategies might represent valid interventions to address MDD + AUD comorbidity.</p><p>Further insights on currently available pharmacological options also appear crucial. An interesting meta-analysis highlighted the efficacy of the Serotonin Antagonist and Reuptake Inhibitor (SARI) nefazodone in treating depression in patients with comorbid AUD [<xref rid="r13" ref-type="bibr">13</xref>]. Also, subsequent results [<xref rid="r9" ref-type="bibr">9</xref>] show that SARIs were second only to disulfiram in increasing abstinent days in MDD + AUD patients while showing similar efficacy to SSRIs in reducing depressive symptoms. However, these promising observations derived from a small number of studies, and additional data could help in clarifying the therapeutic potential of these compounds.</p><p>Trazodone is a SARI antidepressant approved in most countries for the treatment of depressive disorders in adults [<xref rid="r32" ref-type="bibr">32</xref>, <xref rid="r33" ref-type="bibr">33</xref>], it can be administered in several routes (<italic toggle="yes">i.e</italic>., oral, intravenous, intramuscular) and displays multiple mechanisms of action, including relevant serotonin 5-HT2A and &#945;1-adrenergic receptor antagonism, serotonin reuptake inhibition, and weak antihistamine or histamine H1 receptor inverse agonism [<xref rid="r32" ref-type="bibr">32</xref>]. Immediate-release (IR) and extended-release (ER) tablets are available as oral formulations with distinct pharmacodynamic and pharmacokinetic aspects that possibly explain the different effects on specific symptoms [<xref rid="r34" ref-type="bibr">34</xref>, <xref rid="r35" ref-type="bibr">35</xref>].</p><p>Because of its therapeutic flexibility, the off-label use of trazodone is common in clinical practice for many other conditions, including anxiety and sleep problems [<xref rid="r36" ref-type="bibr">36</xref>]. A recent systematic review with meta-analysis on insomnia disorders reported the beneficial effects of trazodone and its ability to optimize the internal structure of sleep, possibly associated with the blockade of 5-HT2 serotonin, H1 histamine, and &#945;1 adaptive receptors. Favorable effects on several polysomnographic parameters have been reported: increased total sleep time, reduced latency to onset of persistent sleep and number of awakenings [<xref rid="r37" ref-type="bibr">37</xref>], restored sleep continuity, slow-wave sleep, and REM phases, which were demonstrated to be specifically altered in patients with depression [<xref rid="r38" ref-type="bibr">38</xref>]. Interestingly, such sedative-hypnotic mechanisms and effects on sleep architecture have been hypothesized to give trazodone also a role in post-traumatic stress disorder (PTSD). A recent report on low dosages of ER formulations combined with a SSRI antidepressant found that PTSD symptoms, especially nightmares, improved until remission and, likely, not only because of the potentiation of SSRIs action in prefrontal cortex areas implied in PTSD pathophysiology [<xref rid="r39" ref-type="bibr">39</xref>].</p><p>Anxiety and sleep problems are usually relevant in AUD and are associated with an increased risk of drinking relapses [<xref rid="r40" ref-type="bibr">40</xref>]. Preliminary reports have shown that low doses of trazodone decreased craving for alcohol, as well as depressive and anxiety symptoms, in a small sample of AUD patients [<xref rid="r41" ref-type="bibr">41</xref>]. Taken together, these observations suggest that trazodone might represent a useful pharmacological option in the treatment of MDD + AUD patients, but data on its effectiveness in this clinical population are still scarce. Therefore, the study aims to retrospectively investigate the effect of extended-release trazodone on depressive symptoms in adults with comorbid MDD and AUD. In addition to assessing mood, we were interested in evaluating anxiety and sleep, measures of craving, overall functioning, and quality of life.</p></sec></sec><sec sec-type="materials|methods" id="sec2"><label>2</label><title>MATERIALS AND METHODS</title><sec id="sec2.1"><label>2.1</label><title>Participants</title><p>We retrospectively evaluated MDD + AUD outpatients, consecutively referring to the Department of Psychiatry of the Fondazione Policlinico Universitario &#8220;A. Gemelli&#8221; IRCCS in Rome, between January 2017 and December 2019. Participants were screened for MDD and AUD according to DSM-5 criteria [<xref rid="r42" ref-type="bibr">42</xref>] and diagnoses confirmed by the Italian version of the Structured Clinical Interview for DSM-5 Disorders Clinician Version (SCID-5-CV) [<xref rid="r43" ref-type="bibr">43</xref>].</p><p>Subjects were considered eligible for the study if having a Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score &#8805; 26, if the current depressive episode lasted for &#8805;3 months, and if abstinent from at least 4 weeks before starting pharmacological treatment. Further inclusion criteria were age 18 to 65 years, at least 8 years of education, and fluency in spoken and written Italian. Exclusion criteria were psychotic features, current substance use disorder (SUD) except for nicotine dependence, major medical disorders or organic brain syndromes, neurocognitive disorders, or significant cognitive impairment based on a Mini-Mental State Examination (MMSE) score &lt; 26 [<xref rid="r44" ref-type="bibr">44</xref>].</p><p>Patients were prescribed extended-release trazodone, both prolonged-release (PR) 75-150 mg tablets and once-a-day (OAD) 150-300 mg formulations, at a flexible dose of 150-300 mg/day (based on clinical evaluation) as part of an integrated therapeutic-rehabilitation program. Prescription of either PR or OAD tablets had been made by clinicians as per routine clinical practice according to patients&#8217; clinical picture, individual needs, and tolerability. All participants were provided continuous psychosocial support throughout the treatment period. Subjects at any time undergoing relapse to heavy drinking, <italic toggle="yes">i.e</italic>., either consuming five (four for women) or more standard drinks on a single occasion or drinking on five or more days in one week after a period of sustained abstinence [<xref rid="r45" ref-type="bibr">45</xref>] or discontinuing the therapeutic-rehabilitation program, were considered dropouts and excluded from subsequent evaluations. Data were obtained from measurements and assessments performed at baseline and after 1, 3, and 6 months of treatment (endpoint).</p><p>The study protocol was conducted following the Good Clinical Practice guidelines and the Declaration of Helsinki (1964) and subsequent revisions and was approved by the Ethics Committee of the Fondazione Policlinico Universitario &#8220;A. Gemelli&#8221; IRCCS, Universit&#224; Cattolica del Sacro Cuore, Rome (Italy).</p></sec><sec id="sec2.2"><label>2.2</label><title>Procedures and Assessment</title><p>Mood symptoms were assessed using MADRS at baseline, 1 month, 3 months, and 6 months [<xref rid="r46" ref-type="bibr">46</xref>]. Patients were considered responders when obtaining an improvement of at least 50% of MADRS baseline scores and remitters when achieving a total score &#8804; 7 at the endpoint, while mood relapses were defined as a new worsening of depressive symptoms (MADRS total score &#8805; 18) after initial improvement.</p><p>Anxiety levels were measured at the same time points using the Hamilton Anxiety Rating Scale (HARS) [<xref rid="r47" ref-type="bibr">47</xref>], while the overall severity of psychiatric symptoms was investigated by the Clinical Global Impression-Severity Scale (CGI-S) [<xref rid="r48" ref-type="bibr">48</xref>] at baseline and endpoint.</p><p>Sleep disturbances were evaluated at all time points by the Pittsburgh Sleep Quality Index (PSQI) [<xref rid="r49" ref-type="bibr">49</xref>], using the cut-off total score of 5 to differentiate &#8220;good&#8221; from &#8220;bad&#8221; sleepers [<xref rid="r50" ref-type="bibr">50</xref>] and by the self-rated Visual Analogue Scale for sleep (VASs) [<xref rid="r51" ref-type="bibr">51</xref>].</p><p>Patients&#8217; functioning and quality of life were assessed by clinicians at baseline and endpoint using the Functioning Assessment Short Test total scores (FAST) [<xref rid="r52" ref-type="bibr">52</xref>] and the Quality of Life Index (QL-I) [<xref rid="r53" ref-type="bibr">53</xref>].</p><p>Craving for alcohol was measured at baseline, 1 month, 3 months, and 6 months by the 14-item Obsessive Compulsive Drinking Scale total scores (OCDS) [<xref rid="r54" ref-type="bibr">54</xref>] and the self-rating instrument Visual Analogue Scale for craving (VASc) [<xref rid="r51" ref-type="bibr">51</xref>].</p><p>Abstinence from alcohol was documented by participants&#8217; self-evaluation and a family member interview. It was further ascertained by blood alcohol concentration, hepatic indices such as aspartate transaminase (AST), alanine transaminase (ALT), gamma glutamyl-transferase (GGT), mean cellular volume (MCV), and blood carbohydrate-deficient transferrin (CDT) detected at each control.</p><p>The safety and tolerability of trazodone were confirmed by physical examination, repeated measurement of body weight, blood pressure, and pulse rate, routine laboratory, and instrumental clinical tests (hematology, chemistry, urinalysis, electrocardiographs with corrected QT interval calculation), and patients&#8217; reports of any adverse events.</p></sec><sec id="sec2.3"><label>2.3</label><title>Statistical Analysis</title><p>Descriptive data were summarized as number and percentage (%) or mean &#177; standard deviation (M &#177; SD) for categorical and continuous variables, respectively. The outcome measures - the mean changes from baseline to 1, 3, and 6 months of each efficacy variable - were analyzed using a mixed model for repeated measurements (MMRM). Analyses were performed on all patients with at least one valid post-baseline assessment of the variables (full-analysis set, FAS). A significance level of 0.05 was used for each test. All analyses were conducted using IBM SPSS Statistics for Windows v. 25.0 (IBM Co., Armonk, New York, USA).</p></sec></sec><sec sec-type="results" id="sec3"><label>3</label><title>RESULTS</title><sec id="sec3.1"><label>3.1</label><title>Demographic and Clinical Data</title><p>One hundred Caucasian subjects with MDD + AUD were included. About half of the sample (48%) reported lifetime substance abuse other than alcohol (cannabis: 18%, benzodiazepines: 15%, cocaine: 12%, opioids: 1%). The following additional pharmacotherapies were assumed throughout the treatment: mood stabilizers/anticonvulsants (valproate, gabapentin, topiramate), atypical antipsychotics (aripiprazole, olanzapine, quetiapine), benzodiazepines (diazepam, lorazepam), specific AUD medications, including acamprosate, nalmefene, and naltrexone.</p><p>Demographic, clinical, and baseline psychometric characteristics are summarized in Table <bold><xref rid="T1" ref-type="table">1</xref></bold>.</p><p>At the endpoint, data were available for 77 subjects. The drop-out rate was 23% (N = 23), of which 9 for relapse to heavy drinking; the total alcohol relapse rate (including minor relapses) was 31.1% (N = 24) of the final sample.</p></sec><sec id="sec3.2"><label>3.2</label><title>Primary Outcome Measures</title><p>Depressive symptoms, expressed as mean MADRS scores, improved during treatment with trazodone (F = 600, <italic toggle="yes">p</italic> &lt; 0.001). Significant changes were already detected after one month of treatment and continued toward endpoint (Table <bold><xref rid="T2" ref-type="table">2</xref></bold>).</p><p>According to MADRS scores at endpoint, 42 patients (54.5%) were classified as &#8220;remitters&#8221;, 19 (24.7%) as &#8220;responders&#8221;, 7 (9.1%) as &#8220;non-responders&#8221;, and 9 (11.7%) as &#8220;relapsers&#8221;.</p></sec><sec id="sec3.3"><label>3.3</label><title>Secondary Outcome Measures</title><p>Improvements from baseline to endpoint were observed in the HARS (F = 952, <italic toggle="yes">p &lt;</italic> 0.001), CGI-S (F = 222, <italic toggle="yes">p &lt;</italic> 0.001), PSQI (F = 747, <italic toggle="yes">p &lt;</italic> 0.001), VASs (F = 522, <italic toggle="yes">p &lt;</italic> 0.001), FAST (F = 337, <italic toggle="yes">p &lt;</italic> 0.001), and QL-I (F = 134, <italic toggle="yes">p &lt;</italic> 0.001) scores (Table <bold><xref rid="T2" ref-type="table">2</xref></bold>).</p><p>At baseline, all patients reached the PSQI cut-off score for sleep disturbances and could be classified as &#8220;bad sleepers&#8221; (baseline score range: 8-17); at the endpoint, only 7.8% (n = 6) still reported bad quality of sleep (endpoint PSQI score range: 2-7).</p><p>All patients could be classified as at least &#8220;moderately ill&#8221; according to baseline CGI-S scores, and 42% of the initial sample was &#8220;markedly&#8221; or &#8220;severely ill&#8221; (CGI-S scores &#8805; 5). At the endpoint, 58% of patients were classified as &#8220;Very Much Improved&#8221; (CGI-I score = 1).</p><p>Patients also displayed a reduction of craving symptoms, as measured by both OCDS (F = 118, <italic toggle="yes">p &lt;</italic> 0.001) and VASc (F = 173, <italic toggle="yes">p &lt;</italic> 0.001) scores (Table <bold><xref rid="T2" ref-type="table">2</xref></bold>).</p></sec><sec id="sec3.4"><label>3.4</label><title>Safety/Tolerability Profile</title><p>Emergent adverse events were detected within the first month of treatment in 25.8% of patients (<italic toggle="yes">i.e</italic>., dizziness/ drowsiness: 19.7%, dry mouth: 6.1%). At 3 months, dizziness/drowsiness was present in only 6.4% of patients and no side effect was reported at 6 months. No patient needed to discontinue treatment because of tolerability concerns.</p><p>Patients displayed significant reductions of MCV (95.1 &#177; 6.78 fl <italic toggle="yes">vs</italic>. 92.2 &#177; 5.71 fl, Z = 3.18, p = 0.001) and liver function tests at 6 months (AST: 26.2 &#177; 6.07 UI/L <italic toggle="yes">vs.</italic> 20.7 &#177; 4.48 UI/L, Z = 3.19, <italic toggle="yes">p</italic> = 0.001; ALT: 27.0 &#177; 9.35 UI/L <italic toggle="yes">vs.</italic> 21.5 &#177; 6.35 UI/L, Z = 3.2, p = 0.001; GGT: 42.5 &#177; 14.65 UI/L <italic toggle="yes">vs.</italic> 27.6 &#177; 7.65 UI/L, Z = 6.18, <italic toggle="yes">p &lt;</italic> 0.001). No changes in QTc interval occurred from baseline to endpoint (405.4 &#177; 26.2 msec <italic toggle="yes">vs.</italic> 407.2 &#177; 26.26 msec, Z = -0.34, <italic toggle="yes">p</italic> = 0.73). A small but significant increase in weight was observed (66.4 &#177; 11.19 kg <italic toggle="yes">vs.</italic> 67.2 &#177; 10.97 kg, Z = -3.2, <italic toggle="yes">p</italic> = 0.002).</p></sec></sec><sec sec-type="discussion" id="sec4"><label>4</label><title>DISCUSSION</title><p>In this naturalistic, retrospective study, we observed that comorbid MDD + AUD patients displayed significant improvement in depressive symptoms following a six-month treatment with extended-release trazodone, with more than half of the sample showing clinical remission. A similar trend was observed in anxiety. Further, treatment with trazodone was associated with a marked improvement in sleep quality. Finally, we observed a reduction of craving symptoms over time as well as an improvement in global functioning and overall quality of life.</p><p>Management and treatment of the comorbidity between MDD and AUD are a concerning public health problem since both disorders reciprocally worsen clinical presentation and outcome. Previous studies on comorbid MDD + AUD provide empirical support for combined pharmacological approaches, where patients are prescribed both antidepressants and medications primarily used in the management of AUD, such as disulfiram and naltrexone [<xref rid="r55" ref-type="bibr">55</xref>]. Subsequent systematic analyses confirmed these findings and supported the use of antidepressants, although pointing out that the clinical relevance of treatment might be modest [<xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r14" ref-type="bibr">14</xref>]. This clinical population is often difficult to manage in real-world practice and, given the lack of comparative trials, the most effective approach is still uncertain [<xref rid="r6" ref-type="bibr">6</xref>].</p><p>Trazodone is a SARI antidepressant and is considered a &#8220;multifunctional&#8221; drug because of its multiple mechanisms of action [<xref rid="r32" ref-type="bibr">32</xref>]. Data from clinical trials suggest that the efficacy of trazodone is comparable to other classes of antidepressants, like SSRIs, SNRIs (serotonin-norepinephrine receptor inhibitors), and TCAs [<xref rid="r56" ref-type="bibr">56</xref>], and recent evidence supports a rapid-onset action, with significant improvements in depressive symptoms within the first weeks of treatment [<xref rid="r57" ref-type="bibr">57</xref>, <xref rid="r58" ref-type="bibr">58</xref>]. Similarly, in our sample of patients with comorbid MDD + AUD, mood improvements were statistically significant after 1 month of treatment and became relevant at the endpoint [<xref rid="r58" ref-type="bibr">58</xref>].</p><p>Trazodone also shows anxiolytic and hypnotic properties, low cardiotoxicity, relatively mild side effects (the most frequent being headaches, dry mouth, fatigue, dizziness, and drowsiness/somnolence), and low potential for abuse. Specifically, extended-release trazodone ensures a gradual release of the drug all over the day, reducing both the plasma peak concentration and dosing frequency. Consequently, blood levels remain constantly above the minimum efficacious antidepressant concentration, and the absence of spikes is associated with lower peak dose adverse effects [<xref rid="r34" ref-type="bibr">34</xref>]. Administration of different formulations could help deliver more targeted interventions and, in turn, improve treatment tolerability and patient adherence [<xref rid="r57" ref-type="bibr">57</xref>]. Indeed, the characteristic pharmacokinetic profile of OAD trazodone makes it particularly useful in patients with moderate/severe depression, mild anxiety, and late insomnia [<xref rid="r32" ref-type="bibr">32</xref>]. Conversely, in light of the higher peak blood concentration, PR trazodone has been suggested in patients with mild/moderate depression, moderate-to-severe anxiety, and more marked difficulties in falling asleep [<xref rid="r35" ref-type="bibr">35</xref>].</p><p>Anxiety is a core symptom of MDD, associated with higher suicidal ideation, worse functioning, greater chronicity, and poor response to antidepressants [<xref rid="r59" ref-type="bibr">59</xref>]. It is also positively correlated with AUD. According to the self-medication theory of substance use, drinking to cope with negative affect (<italic toggle="yes">e.g</italic>., to reduce inner tension and negative feelings) is frequent in subjects with prominent anxiety features [<xref rid="r60" ref-type="bibr">60</xref>] and might transform into a persisting habit through negative reinforcement, <italic toggle="yes">i.e</italic>., reward generated by the reduction of a noxious stimulus [<xref rid="r61" ref-type="bibr">61</xref>, <xref rid="r62" ref-type="bibr">62</xref>]. Higher amounts of alcohol and a fivefold risk of developing a persistent AUD in the following years have been reported in people who drink to cope with anxiety symptoms [<xref rid="r62" ref-type="bibr">62</xref>]. Further, in AUD patients, comorbid anxiety is associated with higher craving, which in turn increases the risk of drinking relapse and overall worse outcomes [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r63" ref-type="bibr">63</xref>]. Trazodone has proven beneficial effects on anxiety in MDD patients and has been widely used as an off-label treatment for generalized anxiety disorders [<xref rid="r35" ref-type="bibr">35</xref>, <xref rid="r36" ref-type="bibr">36</xref>]. Also, a preliminary study has reported that treatment with trazodone has improved anxious symptoms in subjects with AUD [<xref rid="r41" ref-type="bibr">41</xref>].</p><p>Our study confirmed the effectiveness of extended-release trazodone in reducing anxiety in comorbid MDD + AUD patients, with significant improvements observed after the first month of treatment [<xref rid="r58" ref-type="bibr">58</xref>].</p><p>As for sleep disruption, extended-release trazodone has significantly improved sleep in this sample of MDD + AUD patients, further confirming its effectiveness in addressing insomnia in different clinical contexts.</p><p>Sleep disturbances are commonly described in up to 70% of depressive disorders [<xref rid="r64" ref-type="bibr">64</xref>]. Even when effective on mood symptoms, antidepressants do not necessarily improve sleep quality, and residual symptoms of insomnia have been 
reported after successful treatment of depression [<xref rid="r65" ref-type="bibr">65</xref>]. Further, MDD patients with comorbid insomnia are less likely to respond to antidepressant treatment and to achieve functional recovery [<xref rid="r66" ref-type="bibr">66</xref>].</p><p>Sleep disruptions are also common in AUD and insomnia is a significant predictor for psychopathology, including alcohol abuse [<xref rid="r67" ref-type="bibr">67</xref>]. Sleep disturbances have been described both during active drinking and withdrawal, are associated with clinical severity, depressive and anxiety symptoms, craving, and relapses, and have increasingly become a main target of treatment [<xref rid="r40" ref-type="bibr">40</xref>, <xref rid="r68" ref-type="bibr">68</xref>]. Alcohol use might be a dysfunctional self-medicating strategy to address insomnia, leading to repeated drinking, tolerance, and alcohol abuse [<xref rid="r69" ref-type="bibr">69</xref>]. Indeed, the risk of developing AUD is higher in subjects with insomnia, especially when depressive symptoms are also present [<xref rid="r9" ref-type="bibr">9</xref>], and psychiatric burden mediates the relationship between the severity of alcohol use and sleep alterations [<xref rid="r70" ref-type="bibr">70</xref>]. Therefore, insomnia interventions could increase sleep quality and reduce symptoms of depression and anxiety in AUD patients [<xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r71" ref-type="bibr">71</xref>].</p><p>The use of trazodone to treat sleep alterations, especially in patients with psychiatric comorbidities, is a widespread strategy [<xref rid="r72" ref-type="bibr">72</xref>, <xref rid="r73" ref-type="bibr">73</xref>] that yielded beneficial effects in MDD patients [<xref rid="r35" ref-type="bibr">35</xref>, <xref rid="r74" ref-type="bibr">74</xref>] as well as on certain sleep measures and post-withdrawal insomnia in subjects with AUD [<xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r75" ref-type="bibr">75</xref>, <xref rid="r76" ref-type="bibr">76</xref>]. Given that adding trazodone to first-line treatments for insomnia increased rates of remission in non-responding subjects [<xref rid="r77" ref-type="bibr">77</xref>] and the detrimental impact of sleep disruptions on the course of both MDD and AUD, the compound could represent a useful option to effectively address these features in comorbid patients.</p><p>In this study, we found a significant decrease in alcohol craving, both clinician- and self-rated, alongside the improvement of mood, anxiety, and sleep symptoms in comorbid MDD + AUD patients. Craving is a pivotal component of AUD, can be present during both active drinking and withdrawal, figures among the primary predictors of relapse [<xref rid="r78" ref-type="bibr">78</xref>], and should be specifically addressed by pharmacological and psychosocial interventions during AUD treatment [<xref rid="r45" ref-type="bibr">45</xref>, <xref rid="r79" ref-type="bibr">79</xref>-<xref rid="r81" ref-type="bibr">81</xref>]. Further, craving may reciprocally interact with other symptoms, <italic toggle="yes">i.e</italic>., negative affect, anxiety, and insomnia, leading to increased clinical severity and detrimental outcomes [<xref rid="r71" ref-type="bibr">71</xref>, <xref rid="r82" ref-type="bibr">82</xref>, <xref rid="r83" ref-type="bibr">83</xref>]. Preliminary observations reported some effect of trazodone in reducing craving in AUD patients [<xref rid="r41" ref-type="bibr">41</xref>, <xref rid="r84" ref-type="bibr">84</xref>]. Although more studies are needed to confirm these findings, our results further support the usefulness of extended-release trazodone in this clinical population.</p><p>Here, we also observed that extended-release trazodone has improved measures of functioning and quality of life. Both depression and alcohol abuse are associated with poor psychosocial and occupational functioning, with a negative impact on quality of life, requiring increasing attention on functional recovery and quality of life as a main target of therapy.</p><p>Finally, extended-release trazodone showed a favorable safety and tolerability profile in our sample. About &#188; of patients reported mild side effects after 1 month of treatment, which progressively disappeared at the endpoint. Significant improvements in MCV and liver function tests were measured during treatment, possibly reflecting the reduction of alcohol intake. An increase in body weight was observed at the endpoint, although of a modest entity and without medical implications.</p><p>Some limitations must be acknowledged for this study: the retrospective nature of our observations, the relatively small sample size, the lack of a control group, the reliability of the self-administered questionnaires, and the concomitant additional treatments that might have contributed to our findings and limit their generalizability. Further studies involving larger samples and control groups are certainly needed to replicate these results.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The comorbidity of MDD and AUD is complex in terms of both assessment and treatment and yields a great burden on the healthcare system because of increased severity, chronicity, reduced functioning, and generally unfavorable outcomes. Despite the increasing prevalence, patients with alcohol/substance use comorbidity are usually excluded from registration trials; therefore, a study including MDD patients with co-occurring AUD can more closely relate the results to real-world practice. Although several studies tried so far to summarize available findings regarding evidence-based medications and psychosocial interventions to better inform clinical approaches, improvements in treatment for this population are still needed. Patients with comorbid MDD and AUD are usually burdened by several diverse and overlapping features, including higher rates of anxiety, psychomotor agitation, and insomnia, which might be particularly intense in certain phases, <italic toggle="yes">i.e</italic>., withdrawal. These symptoms interact reciprocally and with additional features like craving, increasing the risk for drinking relapses, worsening overall severity, and often requiring combined psychopharmacological approaches to be properly managed. The heterogeneity of comorbid MDD + AUD and key differences within subpopulations could inform personalized, more targeted interventions to improve outcomes. Trazodone has proven to be a valid antidepressant, particularly useful in patients with significant anxiety and insomnia. Also, it appears to exert a beneficial effect on craving. Taken together, these findings suggest that extended-release trazodone might represent a useful pharmacological option in addressing MDD + AUD comorbidity.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>All authors made substantial contributions to the conception and design of the work, acquisition, analysis, and interpretation of data, as well as in drafting the work and revising it critically for important intellectual content. All authors have read and approved the final version of the work.</p></ack><glossary><title>LIST OF ABBREVIATIONS</title><def-list><def-item><term>ALT</term><def><p>Alanine Transaminase</p></def></def-item><def-item><term>AST</term><def><p>Aspartate Transaminase</p></def></def-item><def-item><term>AUD</term><def><p>Alcohol Use Disorder</p></def></def-item><def-item><term>CDT</term><def><p>Carbohydrate-deficient Transferrin</p></def></def-item><def-item><term>GGT</term><def><p>Gamma Glutamyl-transferase</p></def></def-item><def-item><term>MDD</term><def><p>Major Depressive Disorder</p></def></def-item><def-item><term>PTSD</term><def><p>Post-traumatic Stress Disorder</p></def></def-item><def-item><term>RCTs</term><def><p>Randomized Clinical Trials</p></def></def-item><def-item><term>rTMS</term><def><p>Transcranial Magnetic Stimulation</p></def></def-item><def-item><term>SARI</term><def><p>Serotonin Antagonist and Reuptake Inhibitor</p></def></def-item><def-item><term>SSRIs</term><def><p>Selective Serotonin Reuptake Inhibitors</p></def></def-item><def-item><term>SUD</term><def><p>Substance Use Disorder</p></def></def-item><def-item><term>TCAs</term><def><p>Tricyclic Antidepressants</p></def></def-item><def-item><term>tDCS</term><def><p>Transcranial Direct Current Stimulation</p></def></def-item></def-list></glossary><sec sec-type="competing-interests"><title>ETHICS APPROVAL AND CONSENT TO PARTICIPATE</title><p>The study protocol was approved by the Ethics Committee of the Fondazione Policlinico Universitario &#8220;A. Gemelli&#8221; IRCCS, Universit&#224; Cattolica del Sacro Cuore, Rome (Italy).</p></sec><sec sec-type="competing-interests"><title>HUMAN AND ANIMAL RIGHTS</title><p>This is a non-interventional study with data extracted from medical charts of human subjects. Good Clinical Practice guidelines and the Declaration of Helsinki (1964) and subsequent revisions.</p></sec><sec sec-type="competing-interests"><title>CONSENT FOR PUBLICATION</title><p>Not applicable.</p></sec><sec sec-type="data-availability"><title>AVAILABILITY OF DATA AND MATERIALS</title><p>Not applicable.</p></sec><sec sec-type="financial-disclosure"><title>FUNDING</title><p>This independent investigator-initiated study was partially supported by Angelini Pharma.</p></sec><sec sec-type="COI-statement"><title>CONFLICT OF INTEREST</title><p>MDN has been a consultant and/or a speaker who has received research grants from Angelini, Janssen, Lundbeck, Neuraxpharma, and Otsuka. GS has been a consultant and/or a speaker and has received research grants from Angelini, Janssen, Lundbeck, Neuraxpharma, and Otsuka.</p></sec><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="book"><collab>World Health Organization</collab><article-title>Depression and Other Common Mental Disorders: Global Health Estimates.</article-title><publisher-name>Geneva, Switzerland: World Health Organization.</publisher-name><year>2017</year></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="book"><collab>Global Burden of Disease Collaborative Network</collab><article-title>Global Burden of Disease Study 2016 (GBD 2016) Cause-Specific Mortality 1980&#8211;2016.</article-title><publisher-loc>Seattle, WA: Institute for Health Metrics and Evaluation (IHME).</publisher-loc><year>2017</year></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Malhi</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>H.M.X.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990&#8211;2019: Systematic review and meta-analysis.</article-title><source>J. Affect. Disord.</source><year>2020</year><volume>266</volume><fpage>288</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2020.01.141</pub-id><pub-id pub-id-type="pmid">32056890</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puddephatt</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Irizar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gage</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>L.</given-names></name></person-group><article-title>Associations of common mental disorder with alcohol use in the adult general population: a systematic review and meta&#8208;analysis.</article-title><source>Addiction</source><year>2022</year><volume>117</volume><issue>6</issue><fpage>1543</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1111/add.15735</pub-id><pub-id pub-id-type="pmid">34729837</pub-id><pub-id pub-id-type="pmcid">PMC9300028</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuckit</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tipp</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reich</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hesselbrock</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.L.</given-names></name></person-group><article-title>Comparison of induced and independent major depressive disorders in 2,945 alcoholics.</article-title><source>Am. J. Psychiatry</source><year>1997</year><volume>154</volume><issue>7</issue><fpage>948</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1176/ajp.154.7.948</pub-id><pub-id pub-id-type="pmid">9210745</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McHugh</surname><given-names>RK</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>RD</given-names></name></person-group><article-title>Alcohol use disorder and depressive disorders.</article-title><source>Alcohol Res.</source><year>2019</year><volume>40</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.35946/arcr.v40.1.01</pub-id><pub-id pub-id-type="pmcid">PMC6799954</pub-id><pub-id pub-id-type="pmid">31649834</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holma</surname><given-names>I.</given-names></name><name name-style="western"><surname>Isomets&#228;</surname><given-names>E.</given-names></name></person-group><article-title>Comorbid alcohol use disorder in psychiatric MDD patients: A five-year prospective study.</article-title><source>J. Affect. Disord.</source><year>2020</year><volume>267</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2020.02.024</pub-id><pub-id pub-id-type="pmid">32217228</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virtanen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lagerberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khemiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Suvisaari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lichtenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Latvala</surname><given-names>A.</given-names></name></person-group><article-title>Association of selective serotonin re&#8208;uptake inhibitor (SSRI) treatment with acute substance misuse outcomes.</article-title><source>Addiction</source><year>2022</year><volume>117</volume><issue>1</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/add.15625</pub-id><pub-id pub-id-type="pmid">34185347</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms&#8212;A bayesian network meta&#8208;analysis.</article-title><source>CNS Neurosci. Ther.</source><year>2020</year><volume>26</volume><issue>11</issue><fpage>1185</fpage><lpage>1197</lpage><comment>a</comment><pub-id pub-id-type="doi">10.1111/cns.13437</pub-id><pub-id pub-id-type="pmid">32686291</pub-id><pub-id pub-id-type="pmcid">PMC7564195</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redmond</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Buhrmann</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Fuller-Thomson</surname><given-names>E.</given-names></name></person-group><article-title>The Continuum of Recovery from Alcohol Dependence: From Addiction Remission to Complete Mental Health.</article-title><source>Subst. Use Misuse</source><year>2021</year><volume>56</volume><issue>9</issue><fpage>1320</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1080/10826084.2021.1922451</pub-id><pub-id pub-id-type="pmid">34116617</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pignon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baguet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benradia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roelandt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Vaiva</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amad</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Timary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Naassila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geoffroy</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>B.</given-names></name></person-group><article-title>Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.</article-title><source>Drug Alcohol Depend.</source><year>2018</year><volume>187</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.02.009</pub-id><pub-id pub-id-type="pmid">29626745</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Scott-Sheldon</surname><given-names>L.A.J.</given-names></name></person-group><article-title>Insomnia treatment in the context of alcohol use disorder: A systematic review and meta-analysis.</article-title><source>Drug Alcohol Depend.</source><year>2017</year><volume>181</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.09.029</pub-id><pub-id pub-id-type="pmid">29096290</pub-id><pub-id pub-id-type="pmcid">PMC5683932</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iovieno</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tedeschini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Evins</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Papakostas</surname><given-names>G.I.</given-names></name></person-group><article-title>Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.</article-title><source>J. Clin. Psychiatry</source><year>2011</year><volume>72</volume><issue>8</issue><fpage>1144</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.4088/JCP.10m06217</pub-id><pub-id pub-id-type="pmid">21536001</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agabio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trogu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pani</surname><given-names>P.P.</given-names></name></person-group><article-title>Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.</article-title><source>Cochrane Libr.</source><year>2018</year><volume>2018</volume><issue>4</issue><fpage>CD008581</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD008581.pub2</pub-id><pub-id pub-id-type="pmid">29688573</pub-id><pub-id pub-id-type="pmcid">PMC6494437</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hillemacher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frieling</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacotherapeutic options for comorbid depression and alcohol dependence.</article-title><source>Expert Opin. Pharmacother.</source><year>2019</year><volume>20</volume><issue>5</issue><fpage>547</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1080/14656566.2018.1561870</pub-id><pub-id pub-id-type="pmid">30602322</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stokes</surname><given-names>P.R.A.</given-names></name><name name-style="western"><surname>Jokinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Amawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Yatham</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Strang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.H.</given-names></name></person-group><article-title>Pharmacological treatment of mood disorders and comorbid addictions: A systematic review and meta-analysis: traitement pharmacologique des troubles de l&#8217;humeur et des d&#233;pendances comorbides: une revue syst&#233;matique et une m&#233;ta-analyse.</article-title><source>Can. J. Psychiatry</source><year>2020</year><volume>65</volume><issue>11</issue><fpage>749</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1177/0706743720915420</pub-id><pub-id pub-id-type="pmid">32302221</pub-id><pub-id pub-id-type="pmcid">PMC7564307</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>E.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Motala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hempel</surname><given-names>S.</given-names></name></person-group><article-title>Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis.</article-title><source>PLoS Med.</source><year>2021</year><volume>18</volume><issue>10</issue><fpage>e1003822</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1003822</pub-id><pub-id pub-id-type="pmid">34624018</pub-id><pub-id pub-id-type="pmcid">PMC8535380</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fluyau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kailasam</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>C.G.</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2022</year><volume>78</volume><issue>6</issue><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1007/s00228-022-03303-4</pub-id><pub-id pub-id-type="pmid">35246699</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinnikova</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Severtsev</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Komarov</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Vdovin</surname><given-names>A.S.</given-names></name></person-group><article-title>Fluvoksamin v terapii depressivnykh rasstroistv pri alkogol&#8217;noi zavisimosti: rezul&#8217;taty randomizirovannogo otkrytogo sravnitel&#8217;nogo issledovaniya.</article-title><source>Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova</source><year>2021</year><volume>121</volume><issue>12</issue><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.17116/jnevro202112112157</pub-id><pub-id pub-id-type="pmid">35041313</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zastrozhin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skryabin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zastrozhina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grishina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ryzhikova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bure</surname><given-names>I.</given-names></name><name name-style="western"><surname>Golovinskii</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koporov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bryun</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sychev</surname><given-names>D.</given-names></name></person-group><article-title>Effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine in major depressive disorder.</article-title><source>Am. J. Ther.</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>e26</fpage><lpage>e33</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000001388</pub-id><pub-id pub-id-type="pmid">34117140</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zastrozhin</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Skryabin</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Petukhov</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Torrado</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Pankratenko</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Zastrozhina</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Grishina</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ryzhikova</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Shipitsyn</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Bryun</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Sychev</surname><given-names>D.A.</given-names></name></person-group><article-title>Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.</article-title><source>Pharmacogenomics J.</source><year>2021</year><volume>21</volume><issue>4</issue><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/s41397-021-00219-7</pub-id><pub-id pub-id-type="pmid">33608663</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zastrozhin</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Skryabin</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Petukhov</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Pankratenko</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Grishina</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ryzhikova</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Torrado</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Shipitsyn</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Bryun</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Sychev</surname><given-names>D.A.</given-names></name></person-group><article-title>Impact of CYP2D6 polymorphism on equilibrium concentration of fluoxetine in patients diagnosed with major depressive disorder and comorbid alcohol use disorders.</article-title><source>J. Psychiatr. Pract.</source><year>2021</year><volume>27</volume><issue>5</issue><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1097/PRA.0000000000000568</pub-id><pub-id pub-id-type="pmid">34529603</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pepe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Panaccione</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moccia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dattoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Molinaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Janiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>R.S.</given-names></name></person-group><article-title>Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.</article-title><source>CNS Spectr.</source><year>2022</year><volume>27</volume><issue>1</issue><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1017/S109285292000173X</pub-id><pub-id pub-id-type="pmid">32772956</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basurte-Villamor</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vega</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roncero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Raga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grau-L&#243;pez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Torrens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szerman</surname><given-names>N.</given-names></name></person-group><article-title>A Feasibility study of patients with major depression and substance use disorders: vortioxetine as maintenance treatment.</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2022</year><volume>18</volume><fpage>965</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.2147/NDT.S358782</pub-id><pub-id pub-id-type="pmid">35547266</pub-id><pub-id pub-id-type="pmcid">PMC9081619</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Berardis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Anastasia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>A.</given-names></name></person-group><article-title>Novel psychopharmacology for depressive disorders.</article-title><source>Adv. Exp. Med. Biol.</source><year>2021</year><volume>1305</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1007/978-981-33-6044-0_22</pub-id><pub-id pub-id-type="pmid">33834412</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petrakis</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>J.H.</given-names></name></person-group><article-title>Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder.</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><issue>3</issue><fpage>337</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.3990</pub-id><pub-id pub-id-type="pmid">30624551</pub-id><pub-id pub-id-type="pmcid">PMC6439824</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonmez</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Camsari</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Nandakumar</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Voort</surname><given-names>J.L.V.</given-names></name><name name-style="western"><surname>Kung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Croarkin</surname><given-names>P.E.</given-names></name></person-group><article-title>Accelerated TMS for Depression: A systematic review and meta-analysis.</article-title><source>Psychiatry Res.</source><year>2019</year><volume>273</volume><fpage>770</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2018.12.041</pub-id><pub-id pub-id-type="pmid">31207865</pub-id><pub-id pub-id-type="pmcid">PMC6582998</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spano</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pettorruso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoratto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Giuda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giannantonio</surname><given-names>M.</given-names></name></person-group><article-title>Anhedonia across borders: Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes.</article-title><source>CNS Neurosci. Ther.</source><year>2019</year><volume>25</volume><issue>11</issue><fpage>1229</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1111/cns.13230</pub-id><pub-id pub-id-type="pmid">31638332</pub-id><pub-id pub-id-type="pmcid">PMC6834920</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClintock</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Reti</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>L.L.</given-names></name></person-group><article-title>Consensus recommendations for the clinical application of repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of depression.</article-title><source>J Clin Psychiatry</source><year>2018</year><volume>79</volume><issue>1</issue><fpage>16cs10905</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.16cs10905</pub-id><pub-id pub-id-type="pmcid">PMC5846193</pub-id><pub-id pub-id-type="pmid">28541649</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lupi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montemitro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miuli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Natale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spano</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stigliano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tambelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Carlo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Caprio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fraticelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chillemi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pettorruso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sepede</surname><given-names>G.</given-names></name><name name-style="western"><surname>di Giannantonio</surname><given-names>M.</given-names></name></person-group><article-title>Transcranial direct current stimulation reduces craving in substance use disorders.</article-title><source>J. ECT</source><year>2019</year><volume>35</volume><issue>3</issue><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1097/YCT.0000000000000580</pub-id><pub-id pub-id-type="pmid">30844881</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seneviratne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parlatini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solmi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>V.</given-names></name></person-group><article-title>Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials.</article-title><source>Mol. Psychiatry</source><year>2022</year><volume>27</volume><issue>6</issue><fpage>2709</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01524-8</pub-id><pub-id pub-id-type="pmid">35365806</pub-id><pub-id pub-id-type="pmcid">PMC8973679</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagiolini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Comandini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dell&#8217;Osso</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>S.</given-names></name></person-group><article-title>Rediscovering trazodone for the treatment of major depressive disorder.</article-title><source>CNS Drugs</source><year>2012</year><volume>26</volume><issue>12</issue><fpage>1033</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1007/s40263-012-0010-5</pub-id><pub-id pub-id-type="pmid">23192413</pub-id><pub-id pub-id-type="pmcid">PMC3693429</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwasinger-Schmidt</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Macaluso</surname><given-names>M.</given-names></name></person-group><article-title>Other antidepressants.</article-title><source>Handb. Exp. Pharmacol.</source><year>2018</year><volume>250</volume><fpage>325</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1007/164_2018_167</pub-id><pub-id pub-id-type="pmid">30194544</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goracci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Forgione</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>De Giorgi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coluccia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuomo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fagiolini</surname><given-names>A.</given-names></name></person-group><article-title>Practical guidance for prescribing trazodone extended-release in major depression.</article-title><source>Expert Opin. Pharmacother.</source><year>2016</year><volume>17</volume><issue>3</issue><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1517/14656566.2016.1133587</pub-id><pub-id pub-id-type="pmid">26678742</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuomo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bruni</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Decina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Sciascio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fiorentini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scaglione</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vampini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fagiolini</surname><given-names>A.</given-names></name></person-group><article-title>Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.</article-title><source>Riv. Psichiatr.</source><year>2019</year><volume>54</volume><issue>4</issue><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">31379379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1708/3202.31796</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coluccia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casolaro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benbow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amodeo</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Giorgi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fagiolini</surname><given-names>A.</given-names></name></person-group><article-title>Off-Label trazodone prescription: Evidence, benefits and risks.</article-title><source>Curr. Pharm. Des.</source><year>2015</year><volume>21</volume><issue>23</issue><fpage>3343</fpage><lpage>3351</lpage><pub-id pub-id-type="doi">10.2174/1381612821666150619092236</pub-id><pub-id pub-id-type="pmid">26088119</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Y.</given-names></name></person-group><article-title>Trazodone changed the polysomnographic sleep architecture in insomnia disorder: A systematic review and meta-analysis.</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>14453</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-18776-7</pub-id><pub-id pub-id-type="pmid">36002579</pub-id><pub-id pub-id-type="pmcid">PMC9402537</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichniak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wierzbicka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wal&#281;cka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jernajczyk</surname><given-names>W.</given-names></name></person-group><article-title>Effects of antidepressants on sleep.</article-title><source>Curr. Psychiatry Rep.</source><year>2017</year><volume>19</volume><issue>9</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.1007/s11920-017-0816-4</pub-id><pub-id pub-id-type="pmid">28791566</pub-id><pub-id pub-id-type="pmcid">PMC5548844</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berardis</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ventriglio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valchera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vellante</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pettorruso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fraticelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giannantonio</surname><given-names>M.D.</given-names></name></person-group><article-title>Trazodone Add-on in COVID-19-related selective serotonin reuptake inhibitor-resistant post-traumatic stress disorder in healthcare workers: Two case reports.</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2021</year><volume>19</volume><issue>4</issue><fpage>780</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.9758/cpn.2021.19.4.780</pub-id><pub-id pub-id-type="pmid">34690132</pub-id><pub-id pub-id-type="pmcid">PMC8553539</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brower</surname><given-names>K.J.</given-names></name></person-group><article-title>Assessment and treatment of insomnia in adult patients with alcohol use disorders.</article-title><source>Alcohol</source><year>2015</year><volume>49</volume><issue>4</issue><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2014.12.003</pub-id><pub-id pub-id-type="pmid">25957855</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hadjichristos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buonanno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rago</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mannelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Risio</surname><given-names>S.</given-names></name></person-group><article-title>Adjuvant trazodone in the treatment of alcoholism: an open study.</article-title><source>Alcohol Alcohol.</source><year>1998</year><volume>33</volume><issue>4</issue><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.alcalc.a008405</pub-id><pub-id pub-id-type="pmid">9719394</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="book"><collab>American Psychiatric Association</collab><source>Diagnostic and Statistical Manual of Mental Disorders.</source><edition>5th ed</edition><publisher-loc>Arlington, VA</publisher-loc><publisher-name>American Psychiatric Association</publisher-name><year>2013</year></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>First</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.B.W.</given-names></name><name name-style="western"><surname>Karg</surname><given-names>R.S.</given-names></name></person-group><source>Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV).</source><publisher-loc>Arlington, VA</publisher-loc><publisher-name>American Psychiatric Association</publisher-name><year>2016</year></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>P.R.</given-names></name></person-group><article-title>&#8220;Mini-mental state&#8221;.</article-title><source>J. Psychiatr. Res.</source><year>1975</year><volume>12</volume><issue>3</issue><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tedeschi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ortolani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iannoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#8217;Iddio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janiri</surname><given-names>L.</given-names></name></person-group><article-title>Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial.</article-title><source>Alcohol Alcohol.</source><year>2010</year><volume>45</volume><issue>5</issue><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agq039</pub-id><pub-id pub-id-type="pmid">20595193</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>&#197;sberg</surname><given-names>M.</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change.</article-title><source>Br. J. Psychiatry</source><year>1979</year><volume>134</volume><issue>4</issue><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id><pub-id pub-id-type="pmid">444788</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>M.</given-names></name></person-group><article-title>The assessment of anxiety states by rating.</article-title><source>Br. J. Med. Psychol.</source><year>1959</year><volume>32</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.2044-8341.1959.tb00467.x</pub-id><pub-id pub-id-type="pmid">13638508</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>W.</given-names></name></person-group><article-title>Clinical global impression.</article-title><source>ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338)</source><publisher-name>National institute of mental health</publisher-name><publisher-loc>Rockville, MD</publisher-loc><year>1976</year><fpage>218</fpage><lpage>222</lpage></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buysse</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.F.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Monk</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kupfer</surname><given-names>D.J.</given-names></name></person-group><article-title>The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research.</article-title><source>Psychiatry Res.</source><year>1989</year><volume>28</volume><issue>2</issue><fpage>193</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(89)90047-4</pub-id><pub-id pub-id-type="pmid">2748771</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curcio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tempesta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scarlata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moroni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Gennaro</surname><given-names>L.</given-names></name></person-group><article-title>Validity of the italian version of the pittsburgh sleep quality index (PSQI).</article-title><source>Neurol. Sci.</source><year>2013</year><volume>34</volume><issue>4</issue><fpage>511</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s10072-012-1085-y</pub-id><pub-id pub-id-type="pmid">22526760</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mottola</surname><given-names>C.A.</given-names></name></person-group><article-title>Measurement strategies: the visual analogue scale.</article-title><source>Decubitus</source><year>1993</year><volume>6</volume><issue>5</issue><fpage>56</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8286021</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>S&#225;nchez-Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Aran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salamero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torrent</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reinares</surname><given-names>M.</given-names></name><name name-style="western"><surname>Comes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colom</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Riel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ayuso-Mateos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kapczinski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vieta</surname><given-names>E.</given-names></name></person-group><article-title>Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder.</article-title><source>Clin. Pract. Epidemiol. Ment. Health</source><year>2007</year><volume>3</volume><issue>1</issue><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-3-5</pub-id><pub-id pub-id-type="pmid">17555558</pub-id><pub-id pub-id-type="pmcid">PMC1904447</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spitzer</surname><given-names>W.O.</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chesterman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>R.</given-names></name><name name-style="western"><surname>Battista</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Catchlove</surname><given-names>B.R.</given-names></name></person-group><article-title>Measuring the quality of life of cancer patients.</article-title><source>J. Chronic Dis.</source><year>1981</year><volume>34</volume><issue>12</issue><fpage>585</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/0021-9681(81)90058-8</pub-id><pub-id pub-id-type="pmid">7309824</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anton</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Moak</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Latham</surname><given-names>P.</given-names></name></person-group><article-title>The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior.</article-title><source>Alcohol. Clin. Exp. Res.</source><year>1995</year><volume>19</volume><issue>1</issue><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.1995.tb01475.x</pub-id><pub-id pub-id-type="pmid">7771669</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name></person-group><article-title>Effect of alcohol use disorders and alcohol intake on the risk of subsequent depressive symptoms: a systematic review and meta&#8208;analysis of cohort studies.</article-title><source>Addiction</source><year>2020</year><volume>115</volume><issue>7</issue><fpage>1224</fpage><lpage>1243</lpage><comment>b</comment><pub-id pub-id-type="doi">10.1111/add.14935</pub-id><pub-id pub-id-type="pmid">31837230</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papakostas</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.</article-title><source>Eur. Psychiatry</source><year>2007</year><volume>22</volume><issue>7</issue><fpage>444</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2007.01.1220</pub-id><pub-id pub-id-type="pmid">17418537</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagiolini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ferrando</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muntean</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#225;lov&#225;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Comandini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Dato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Loreto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Salvatori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tongiani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>S.</given-names></name></person-group><article-title>A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.</article-title><source>Int. Clin. Psychopharmacol.</source><year>2020</year><volume>35</volume><issue>3</issue><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1097/YIC.0000000000000304</pub-id><pub-id pub-id-type="pmid">31972628</pub-id><pub-id pub-id-type="pmcid">PMC7099841</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lamba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action.</article-title><source>CNS Spectr.</source><year>2021</year><volume>26</volume><issue>3</issue><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1017/S1092852921000304</pub-id><pub-id pub-id-type="pmid">33731232</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demyttenaere</surname><given-names>K.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Widiger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wittchen</surname><given-names>H.U.</given-names></name></person-group><article-title>The clinical characterization of the adult patient with depression aimed at personalization of management.</article-title><source>World Psychiatry</source><year>2020</year><volume>19</volume><issue>3</issue><fpage>269</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1002/wps.20771</pub-id><pub-id pub-id-type="pmid">32931110</pub-id><pub-id pub-id-type="pmcid">PMC7491646</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sareen</surname><given-names>J.</given-names></name></person-group><article-title>Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature.</article-title><source>Depress. Anxiety</source><year>2018</year><volume>35</volume><issue>9</issue><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1002/da.22771</pub-id><pub-id pub-id-type="pmid">29999576</pub-id><pub-id pub-id-type="pmcid">PMC6175215</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crum</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mojtabai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lazareck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sareen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Green</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>La Flair</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alvanzo</surname><given-names>A.A.H.</given-names></name><name name-style="western"><surname>Storr</surname><given-names>C.L.</given-names></name></person-group><article-title>A prospective assessment of reports of drinking to self-medicate mood symptoms with the incidence and persistence of alcohol dependence.</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><issue>7</issue><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.1098</pub-id><pub-id pub-id-type="pmid">23636710</pub-id><pub-id pub-id-type="pmcid">PMC4151472</pub-id></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anker</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>M.G.</given-names></name></person-group><article-title>Co-occurring alcohol use disorder and anxiety: Bridging psychiatric, psychological, and neurobiological perspectives.</article-title><source>Alcohol Res</source><year>2019</year><volume>40</volume><issue>1</issue><comment>.</comment><pub-id pub-id-type="pmid">31886106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.35946/arcr.v40.1.03</pub-id><pub-id pub-id-type="pmcid">PMC6927748</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coates</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gullo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Feeney</surname><given-names>G.F.X.</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>J.P.</given-names></name></person-group><article-title>Relationship between alcohol craving dimensions and features of comorbid mental health in an alcohol dependent sample.</article-title><source>Addict. Behav.</source><year>2022</year><volume>124</volume><fpage>107106</fpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2021.107106</pub-id><pub-id pub-id-type="pmid">34530206</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soehner</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>A.G.</given-names></name></person-group><article-title>Prevalence and functional consequences of severe insomnia symptoms in mood and anxiety disorders: results from a nationally representative sample.</article-title><source>Sleep</source><year>2012</year><volume>35</volume><issue>10</issue><fpage>1367</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.5665/sleep.2116</pub-id><pub-id pub-id-type="pmid">23024435</pub-id><pub-id pub-id-type="pmcid">PMC3443763</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troxel</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Kupfer</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.F.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Frank</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thase</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Miewald</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Buysse</surname><given-names>D.J.</given-names></name></person-group><article-title>Insomnia and objectively measured sleep disturbances predict treatment outcome in depressed patients treated with psychotherapy or psychotherapy-pharmacotherapy combinations.</article-title><source>J. Clin. Psychiatry</source><year>2012</year><volume>73</volume><issue>4</issue><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.4088/JCP.11m07184</pub-id><pub-id pub-id-type="pmid">22152403</pub-id><pub-id pub-id-type="pmcid">PMC3310298</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carney</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>Z.V.</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>A.D.</given-names></name></person-group><article-title>A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder.</article-title><source>J. Clin. Psychiatry</source><year>2007</year><volume>68</volume><issue>2</issue><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n0211</pub-id><pub-id pub-id-type="pmid">17335324</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hertenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feige</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gmeiner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kienzler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spiegelhalder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jansson-Fr&#246;jmark</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palagini</surname><given-names>L.</given-names></name><name name-style="western"><surname>R&#252;cker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Riemann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baglioni</surname><given-names>C.</given-names></name></person-group><article-title>Insomnia as a predictor of mental disorders: A systematic review and meta-analysis.</article-title><source>Sleep Med. Rev.</source><year>2019</year><volume>43</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.smrv.2018.10.006</pub-id><pub-id pub-id-type="pmid">30537570</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolla</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Mansukhani</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Biernacka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chakravorty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karpyak</surname><given-names>V.M.</given-names></name></person-group><article-title>Sleep disturbances in early alcohol recovery: Prevalence and associations with clinical characteristics and severity of alcohol consumption.</article-title><source>Drug Alcohol Depend.</source><year>2020</year><volume>206</volume><fpage>107655</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107655</pub-id><pub-id pub-id-type="pmid">31744670</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Deroche</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>McCrae</surname><given-names>C.S.</given-names></name></person-group><article-title>Sleep and alcohol use among young adult drinkers with Insomnia: A daily process model.</article-title><source>Addict. Behav.</source><year>2021</year><volume>119</volume><fpage>106911</fpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2021.106911</pub-id><pub-id pub-id-type="pmid">33773200</pub-id><pub-id pub-id-type="pmcid">PMC8113078</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kolla</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Kampman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Chakravorty</surname><given-names>S.</given-names></name></person-group><article-title>The relationship between insomnia and the intensity of drinking in treatment-seeking individuals with alcohol dependence.</article-title><source>Drug Alcohol Depend.</source><year>2020</year><volume>215</volume><fpage>108189</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108189</pub-id><pub-id pub-id-type="pmid">32768993</pub-id><pub-id pub-id-type="pmcid">PMC10082590</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wo&#322;y&#324;yczyk-Gmaj</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jakubczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trucco</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kobyli&#324;ski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zaorska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gmaj</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kopera</surname><given-names>M.</given-names></name></person-group><article-title>Emotional dysregulation, anxiety symptoms and insomnia in individuals with alcohol use disorder.</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><issue>5</issue><fpage>2700</fpage><pub-id pub-id-type="doi">10.3390/ijerph19052700</pub-id><pub-id pub-id-type="pmid">35270392</pub-id><pub-id pub-id-type="pmcid">PMC8910121</pub-id></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everitt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lipinska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mayers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malizia</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Manson</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.</given-names></name></person-group><article-title>Antidepressants for insomnia in adults.</article-title><source>Cochrane Database Syst. Rev.</source><year>2018</year><volume>5</volume><issue>5</issue><fpage>CD010753</fpage><pub-id pub-id-type="pmid">29761479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010753.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6494576</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pochiero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gorini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Comandini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calisti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loreto</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>T.</given-names></name><name name-style="western"><surname>Anastassopoulos</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bruni</surname><given-names>O.</given-names></name></person-group><article-title>Real-world characteristics and treatment patterns of patients with insomnia prescribed trazodone in the United States.</article-title><source>Clin Ther.</source><year>2022</year><volume>2022</volume><fpage>S0149-2918(22)00235-1</fpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2022.07.004</pub-id><pub-id pub-id-type="pmid">36041931</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheehan</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Rozova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gossen</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Gibertini</surname><given-names>M.</given-names></name></person-group><article-title>The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.</article-title><source>Psychopharmacol. Bull.</source><year>2009</year><volume>42</volume><issue>4</issue><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20581790</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedmann</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Swift</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Millman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.D.</given-names></name></person-group><article-title>Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial.</article-title><source>Alcohol. Clin. Exp. Res.</source><year>2008</year><volume>32</volume><issue>9</issue><fpage>1652</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2008.00742.x</pub-id><pub-id pub-id-type="pmid">18616688</pub-id><pub-id pub-id-type="pmcid">PMC2567128</pub-id></element-citation></ref><ref id="r76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolla</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Mansukhani</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Schneekloth</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacological treatment of insomnia in alcohol recovery: a systematic review.</article-title><source>Alcohol Alcohol.</source><year>2011</year><volume>46</volume><issue>5</issue><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agr073</pub-id><pub-id pub-id-type="pmid">21715413</pub-id></element-citation></ref><ref id="r77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Beaulieu-Bonneau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Guay</surname><given-names>B.</given-names></name><name name-style="western"><surname>B&#233;langer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cartwright</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lamy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Busby</surname><given-names>M.</given-names></name></person-group><article-title>Effectiveness of sequential psychological and medication therapies for insomnia disorder.</article-title><source>JAMA Psychiatry</source><year>2020</year><volume>77</volume><issue>11</issue><fpage>1107</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.1767</pub-id><pub-id pub-id-type="pmid">32639561</pub-id><pub-id pub-id-type="pmcid">PMC7344835</pub-id></element-citation></ref><ref id="r78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavicchioli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vassena</surname><given-names>G.</given-names></name><name name-style="western"><surname>Movalli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maffei</surname><given-names>C.</given-names></name></person-group><article-title>Is craving a risk factor for substance use among treatment-seeking individuals with alcohol and other drugs use disorders? A meta-analytic review.</article-title><source>Drug Alcohol Depend.</source><year>2020</year><volume>212</volume><fpage>108002</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108002</pub-id><pub-id pub-id-type="pmid">32413635</pub-id></element-citation></ref><ref id="r79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Vita</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hatzigiakoumis</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Guglielmo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santucci</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aliotta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Romanelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Verrastro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petruccelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Giannantonio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janiri</surname><given-names>L.</given-names></name></person-group><article-title>Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study.</article-title><source>J. Clin. Psychopharmacol.</source><year>2014</year><volume>34</volume><issue>6</issue><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000228</pub-id><pub-id pub-id-type="pmid">25275672</pub-id></element-citation></ref><ref id="r80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.</given-names></name></person-group><article-title>Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.</article-title><source>Addiction</source><year>2018</year><volume>113</volume><issue>8</issue><fpage>1396</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1111/add.14191</pub-id><pub-id pub-id-type="pmid">29479827</pub-id></element-citation></ref><ref id="r81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>W.W.</given-names></name></person-group><article-title>Anticraving therapy for alcohol use disorder: A clinical review.</article-title><source>Neuropsychopharmacol. Rep.</source><year>2018</year><volume>38</volume><issue>3</issue><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1002/npr2.12028</pub-id><pub-id pub-id-type="pmid">30175522</pub-id><pub-id pub-id-type="pmcid">PMC7292332</pub-id></element-citation></ref><ref id="r82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Andreoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ortolani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tedeschi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fanella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iannoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#8217;Iddio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prof</surname><given-names>L.J.</given-names></name></person-group><article-title>Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects.</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2011</year><volume>35</volume><issue>4</issue><fpage>953</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.01.013</pub-id><pub-id pub-id-type="pmid">21256179</pub-id></element-citation></ref><ref id="r83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cyr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedinielli</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cutarella</surname><given-names>C.</given-names></name><name name-style="western"><surname>Br&#233;jard</surname><given-names>V.</given-names></name></person-group><article-title>Association between negative affectivity and craving in substance-related disorders: a systematic review and meta-analysis of direct and indirect relationships.</article-title><source>Psychol. Rep.</source><year>2022</year><pub-id pub-id-type="doi">10.1177/00332941211061079</pub-id><pub-id pub-id-type="pmid">35105221</pub-id></element-citation></ref><ref id="r84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borras</surname><given-names>L.</given-names></name><name name-style="western"><surname>Timary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Constant</surname><given-names>E-L.</given-names></name><name name-style="western"><surname>Huguelet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eytan</surname><given-names>A.</given-names></name></person-group><article-title>Successful treatment of alcohol withdrawal with trazodone.</article-title><source>Pharmacopsychiatry</source><year>2006</year><volume>39</volume><issue>6</issue><fpage>232</fpage><pub-id pub-id-type="doi">10.1055/s-2006-951385</pub-id><pub-id pub-id-type="pmid">17124647</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Sociodemographic and clinical characteristics at baseline.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">
<bold>N %; M &#177; SD</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
&#160;&#160;&#160;<bold>Overall</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td colspan="2" valign="top" align="center" scope="col" rowspan="1">
<bold>Sociodemographic Features</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">47.4 &#177; 12.5</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
&#160;&#160;&#160;<bold>Gender</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Male<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Female</td><td valign="top" align="center" rowspan="1" colspan="1">57 (57)<break/>43 (43)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Education level (years)</td><td valign="top" align="center" rowspan="1" colspan="1">13.9 &#177; 3.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Occupation (employed)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (65)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Marital status (married)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (22)</td></tr><tr><td colspan="2" valign="top" align="center" scope="col" rowspan="1">
<bold>Clinical Data</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Age of onset (years)</td><td valign="top" align="center" rowspan="1" colspan="1">34.6 &#177; 13</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Duration of illness (years)</td><td valign="top" align="center" rowspan="1" colspan="1">12.7 &#177; 8.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Number of lifetime episodes</td><td valign="top" align="center" rowspan="1" colspan="1">3.1 &#177; 1.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Duration of the current episode (months)</td><td valign="top" align="center" rowspan="1" colspan="1">3.7 &#177; 0.6</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Suicide attempts</td><td valign="top" align="center" rowspan="1" colspan="1">10 (10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Trazodone dose (mg/day)</td><td valign="top" align="center" rowspan="1" colspan="1">192 &#177; 67.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;<bold>Other Psychopharmacotherapy</bold><break/>&#160;&#160;&#160;&#160;&#160;&#160;Mood stabilizers/anticonvulsants<break/>&#160;&#160;&#160;&#160;&#160;&#160;Atypical antipsychotics<break/>&#160;&#160;&#160;&#160;&#160;&#160;Sedative-hypnotics/anxiolytics<break/>&#160;&#160;&#160;&#160;&#160;&#160;Anti-craving drugs</td><td valign="top" align="center" rowspan="1" colspan="1">66 (66)<break/>51 (51)<break/>12 (12)<break/>17 (17)<break/>41 (41)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Family history of psychiatric disorders</td><td valign="top" align="center" rowspan="1" colspan="1">61 (61)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Medical comorbidities</td><td valign="top" align="center" rowspan="1" colspan="1">28 (28)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Smoking habits</td><td valign="top" align="center" rowspan="1" colspan="1">70 (70)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;BMI</td><td valign="top" align="center" rowspan="1" colspan="1">23.6 &#177; 3.6</td></tr><tr><td colspan="2" valign="top" align="center" scope="col" rowspan="1">
<bold>Psychometric Assessment</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;MADRS</td><td valign="top" align="center" rowspan="1" colspan="1">27.4 &#177; 2.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;HARS</td><td valign="top" align="center" rowspan="1" colspan="1">23.8 &#177; 3.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;CGI-S</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 &#177; 0.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;PSQI</td><td valign="top" align="center" rowspan="1" colspan="1">12.8 &#177; 2.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;VASs</td><td valign="top" align="center" rowspan="1" colspan="1">6.7 &#177; 0.6</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;FAST</td><td valign="top" align="center" rowspan="1" colspan="1">46.4 &#177; 6.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;QL-I</td><td valign="top" align="center" rowspan="1" colspan="1">5.3 &#177; 0.6</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;OCDS</td><td valign="top" align="center" rowspan="1" colspan="1">21.9 &#177; 8.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;VASc</td><td valign="top" align="center" rowspan="1" colspan="1">6.9 &#177; 1.6</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviations:</bold> BMI: Body Mass Index, CGI: Clinical Global Impression, FAST: Functioning Assessment Short Test, HARS: Hamilton Anxiety Rating Scale, M: Mean, MADRS: Montgomery-&#197;sberg Depression Rating Scale, OCDS: Obsessive Compulsive Drinking Scale, PSQI: Pittsburgh Sleep Quality Index, QL-I: Quality of Life Index, SD: Standard Deviation, VASc: Visual Analogue Scale for craving, VASs: Visual Analogue Scale for sleep.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Psychometric evaluation at selected time-points (MMRM, FAS).</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"/><th valign="middle" colspan="5" align="center" scope="colgroup" rowspan="1">
<bold>Change from Baseline</bold>
</th></tr></thead><tbody><tr><td rowspan="2" valign="middle" align="left" scope="row" colspan="1"/><td rowspan="2" valign="middle" align="center" colspan="1">
<bold>Mean &#177; SD</bold>
</td><td rowspan="2" valign="middle" align="center" colspan="1">
<bold>Mean &#177; SE</bold>
</td><td valign="middle" colspan="2" align="center" rowspan="1">
<bold>95% Confidence Interval</bold>
</td><td rowspan="2" valign="middle" align="center" colspan="1">
<bold>
<italic toggle="yes">t</italic>
</bold>
</td><td rowspan="2" valign="middle" align="center" colspan="1">
<bold>
<italic toggle="yes">p</italic>
</bold>
</td></tr><tr><td valign="middle" colspan="1" align="center" scope="row" rowspan="1">
<bold>Lower</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>Upper</bold>
</td></tr><tr><td colspan="7" valign="top" align="center" scope="col" rowspan="1">
<bold>Psychiatric Symptoms</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;MADRS<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">24.2 &#177; 1.98<break/>14.4 &#177; 2.75<break/>8.68 &#177; 4.95</td><td valign="middle" align="center" rowspan="1" colspan="1">-3.41 &#177; 0.48<break/>-12.9 &#177; 0.49<break/>-18.8 &#177; 0.49</td><td valign="middle" align="center" rowspan="1" colspan="1">-4.37<break/>-13.91<break/>-19.7</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.47<break/>-11.97<break/>-17.77</td><td valign="middle" align="center" rowspan="1" colspan="1">-7.04<break/>-26.15<break/>-38.09</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;HARS<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">20.05 &#177; 3.1<break/>14.09 &#177; 2.84<break/>9.04 &#177; 2.18</td><td valign="middle" align="center" rowspan="1" colspan="1">-3.57 &#177; 0.29<break/>-9.36 &#177; 0.30<break/>-15.19 &#177; 0.31</td><td valign="middle" align="center" rowspan="1" colspan="1">-4.15<break/>-9.95<break/>-15.79</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.98<break/>-8.77<break/>-14.6</td><td valign="middle" align="center" rowspan="1" colspan="1">-12<break/>-31<break/>-49.9</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;CGI-S<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">2.35 &#177; 0.53</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.04 &#177; 0.04</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.13</td><td valign="middle" align="center" rowspan="1" colspan="1">-1.96</td><td valign="middle" align="center" rowspan="1" colspan="1">-47.1</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td colspan="7" valign="top" align="center" scope="col" rowspan="1">
<bold>Sleep Quality</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;PSQI<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">10.4 &#177; 1.86<break/>7.08 &#177; 1.43<break/>4.12 &#177; 1.41</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.4 &#177; 0.33<break/>-5.7 &#177; 0.34<break/>-8.89 &#177; 0.35</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.9<break/>-6.29<break/>-9.48</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.02<break/>-5.4<break/>-8.38</td><td valign="middle" align="center" rowspan="1" colspan="1">-12.6<break/>-29.1<break/>-44.4</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;VASs<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">5.74 &#177; 0.74<break/>4.14 &#177; 0.95<break/>2.15 &#177; 1.17</td><td valign="middle" align="center" rowspan="1" colspan="1">-1.02 &#177; 0.24<break/>-2.59 &#177; 0.25<break/>-4.57 &#177; 0.26</td><td valign="middle" align="center" rowspan="1" colspan="1">-1.21<break/>-2.83<break/>-4.81</td><td valign="middle" align="center" rowspan="1" colspan="1">-0.79<break/>-2.41<break/>-4.39</td><td valign="middle" align="center" rowspan="1" colspan="1">-9.4<break/>-24.6<break/>-42.69</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td colspan="7" valign="top" align="center" scope="col" rowspan="1">
<bold>Measures of Craving</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;OCDS<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">18.4 &#177; 6.01<break/>12 &#177; 4.18<break/>6.29 &#177; 3.26</td><td valign="middle" align="center" rowspan="1" colspan="1">-3.99 &#177; 1.95<break/>-10.4 &#177; 1.85<break/>-16.11 &#177; 1.99</td><td valign="middle" align="center" rowspan="1" colspan="1">-5.72<break/>-12.2<break/>-17.91</td><td valign="middle" align="center" rowspan="1" colspan="1">-2.19<break/>-8.6<break/>-12.3</td><td valign="middle" align="center" rowspan="1" colspan="1">-4.33<break/>-11.28<break/>-17.47</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;VASc<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;3 m<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">6.22 &#177; 1.18<break/>4.56 &#177; 1.15<break/>2.5 &#177; 1.43</td><td valign="middle" align="center" rowspan="1" colspan="1">-0.77 &#177; 0.20<break/>-2.43 &#177; 0.21<break/>-4.48 &#177; 0.22</td><td valign="middle" align="center" rowspan="1" colspan="1">-1.18<break/>-2.84<break/>-4.89</td><td valign="middle" align="center" rowspan="1" colspan="1">-0.37<break/>-2.02<break/>-4.06</td><td valign="middle" align="center" rowspan="1" colspan="1">-3.72<break/>-11.69<break/>-21.07</td><td valign="middle" align="center" rowspan="1" colspan="1">0.03<break/>&lt; 0.001<break/>&lt; 0.001</td></tr><tr><td colspan="7" valign="top" align="center" scope="col" rowspan="1">
<bold>Clinician-rated Functioning</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;FAST<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">27.5 &#177; 5.32</td><td valign="middle" align="center" rowspan="1" colspan="1">-19 &#177; 1.08</td><td valign="middle" align="center" rowspan="1" colspan="1">-20.9</td><td valign="middle" align="center" rowspan="1" colspan="1">-17</td><td valign="middle" align="center" rowspan="1" colspan="1">-19.1</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td colspan="7" valign="top" align="center" scope="col" rowspan="1">
<bold>Quality of Life</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;QL-I<break/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;6 m</td><td valign="middle" align="center" rowspan="1" colspan="1">6.79 &#177; 0.51</td><td valign="middle" align="center" rowspan="1" colspan="1">1.56 &#177; 0.1</td><td valign="middle" align="center" rowspan="1" colspan="1">1.3</td><td valign="middle" align="center" rowspan="1" colspan="1">1.83</td><td valign="middle" align="center" rowspan="1" colspan="1">11.6</td><td valign="middle" align="center" rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviations:</bold> CGI-S: Clinical Global Impression - Severity Scale, FAST: Functional Assessment Short Test, HARS: Hamilton Anxiety Rating Scale, MADRS: Montgomery-&#197;sberg Depression Rating Scale, OCDS: Obsessive Compulsive Drinking Scale, p: p-value, PSQI: Pittsburgh Sleep Quality Index, QL-I: Quality of Life Index, SD: standard deviation, SE: standard error, VASc: Visual Analogue Scale for craving, VASs: Visual Analogue scale for sleep.</p></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>